{
    "nctId": "NCT00165308",
    "briefTitle": "Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors",
    "officialTitle": "A Feasibility Study of Tamoxifen Prevention of Breast Cancer in Hodgkin's Disease Survivors",
    "overallStatus": "COMPLETED",
    "conditions": "Hodgkin's Disease, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 29,
    "primaryOutcomeMeasure": "To determine the feasibility of a randomized trial testing the effectiveness of tamoxifen in reducing the risk of radiogenic breast cancer.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Females diagnosed with Hodgkin's Disease at age \\< 35 years\n* \\> 5 years from mantle or chest radiation\n* Current age \\> 30 years\n* Has completed childbearing\n* Willingness to discontinue use of oral contraceptives or other hormonal contraception for duration of the study\n\nExclusion Criteria:\n\n* History of secondary malignancy after Hodgkin's disease, except thyroid cancer of basal cell cancer\n* Recurrence of Hodgkin's disease in the 5 years before study entry\n* Current participation in any other cancer prevention study\n* Current or prior use of tamoxifen\n* Current use of coumadin\n* History of deep venous thrombosis, pulmonary embolism, or a condition known to be associated with hypercoagulability\n* History of cerebrovascular accident\n* History of macular degeneration\n* Current use of chemotherapy for benign disease",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}